Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NORA DANIEL

Allopathic & Osteopathic Physicians Pediatrics

NPI
1720183106
CMS profile
32608
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$114.62

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $114.62 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI-AVENTIS U.S. LLC $114.62 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NORA DANIEL

NPI 1720183106 · CMS profile ID 32608

Allopathic & Osteopathic Physicians / Pediatrics

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NORA DANIEL, NPI 1720183106, CMS profile ID 32608. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NORA DANIEL, NPI 1720183106, CMS profile ID 32608. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NORA DANIEL, NPI 1720183106, CMS profile ID 32608, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $114.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $114.6204/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139598723 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.80 1
PY2022 $140.81 2
PY2023 $1,353.47 10
PY2024 $114.62 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,328,285.04 535
PY2024 Principal investigator $517,981.68 120
PY2023 Principal investigator $685,808.52 880
PY2022 Principal investigator $908,256.60 1,978

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,978 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 12/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938715983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,850.00 10/13/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938699325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46,950.00 09/22/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938695769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 09/19/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938694067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938686997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938687997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938688999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938689999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938690999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.40 09/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938691083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 08/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938679537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938669999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938670997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 07/28/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938671255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938655999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938656997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938657995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 07/11/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938658185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938634995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 06/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938635853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 05/05/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938626113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 05/02/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938625395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/21/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938623333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938619999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $794.50 04/01/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 938620157
Principal investigator 1 Allergan, Inc. $6,000.00 01/24/2022 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 864368441